MedTrace Logo

A Pilot Study of Inflammatory Markers in Alzheimer's Disease

NCT00715858 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2009-02-04

No results posted yet for this study

Summary

The purpose of this study is to examine the cerebrospinal fluid (CSF) of patients with Alzheimer's disease for biomarkers of inflammation and their response to the antibiotics doxycycline and rifampin. The results of this preliminary analysis will be used in defining the direction of further research.

Conditions

Interventions

DRUG

doxycycline

capsule, 100 mg, b.i.d., 12 months

DRUG

rifampin

capsule, 300 mg, od, 12 months

DRUG

placebo

placebo matched to rifampin; placebo matched to doxycycline

Sponsors & Collaborators

  • The Physicians' Services Incorporated Foundation

    collaborator OTHER

  • McMaster University

    lead OTHER

Principal Investigators

  • D.William Molloy, MB, MRCPI, FRCPC · McMaster University

  • Brandon M Kucher, PhD, MD · McMaster University

  • Shucui Jiang, MD,PhD · McMaster University

  • Michel P Rathbone, MB, PhD · McMaster University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-08-31
Completion
2009-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00715858 on ClinicalTrials.gov